Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Clinical analysis of NSCLC patients reveals lack of association between EGFR mutation and TET1 downregulation


Lung cancer is one of the leading causes of death from cancer worldwide, with a poor prognosis in advanced cases. In the past decade, epidermal growth factor receptor (EGFR) inhibitors have shown significant efficacy towards treatment for EGFR mutant lung cancer. Expanding our knowledge of oncogenic EGFR signaling pathways is therefore of highly importance for the cancer field. Recently it has been proposed that mutant EGFR transcriptionally silences the TET1 (ten–eleven translocation methylcytosine dioxygenase 1) gene in cellular and animal models of lung cancer. Since TET1 is a known DNA demethylase, EGFR-mediated TET1 silencing therefore downregulates demethylation of tumor suppressor genes, which then leads to tumor growth inhibition, potentiating the role of TET1 as a tumor suppressor gene in NSCLC. In our study, we examined the role of EGFR-TET1 silencing in NSCLC patient samples. By independently analyzing the TCGA (The Cancer Genome Atlas) NSCLC data set as well as a cohort of patient samples from our hospital and a data set from publicly deposited databases, we did not observe the aforementioned mutant EGFR silencing of TET1. Conversely, in our cohort, TET1 expression levels were significantly elevated in EGFR mutant samples (P=0.007). Patients with higher TET1 levels showed a trend of better response rates to EGFR inhibitors compared to low TET1 staining levels, although the result was not significant (P=0.08). Furthermore, we did not observe a correlation between TET1 expression levels and patient survival. We conclude that while oncogenic EGFR suppression of TET1 is established in cellular and animal models of lung cancer, its role in patient outcome and prognosis remains inconclusive and warrants further investigation.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4


  1. Woodard GA, Jones KD, Jablons DM . Lung cancer staging and prognosis. Cancer Treat Res 2016; 170: 47–75.

    Article  Google Scholar 

  2. Ciardiello F, Tortora G . EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160–1174.

    Article  CAS  Google Scholar 

  3. Burotto M, Manasanch EE, Wilkerson J, Fojo T . Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist 2015; 20: 400–410.

    Article  CAS  Google Scholar 

  4. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327–3334.

    Article  CAS  Google Scholar 

  5. Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372: 1689–1699.

    Article  Google Scholar 

  6. Hatzimichael E, Crook T . Cancer epigenetics: new therapies and new challenges. J Drug Deliv 2013; 2013: 529312.

    Article  Google Scholar 

  7. Herman JG, Baylin SB . Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042–2054.

    Article  CAS  Google Scholar 

  8. Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 2007; 109: 713–717.

    Article  CAS  Google Scholar 

  9. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562–569.

    Article  CAS  Google Scholar 

  10. Kumar S, Cheng X, Klimasauskas S, Mi S, Posfai J, Roberts RJ et al. The DNA (cytosine-5) methyltransferases. Nucleic Acids Res 1994; 22: 1–10.

    Article  CAS  Google Scholar 

  11. Robertson KD . DNA methylation, methyltransferases, and cancer. Oncogene 2001; 20: 3139–3155.

    Article  CAS  Google Scholar 

  12. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324: 930–935.

    Article  CAS  Google Scholar 

  13. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y . Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466: 1129–1133.

    Article  CAS  Google Scholar 

  14. Ko M, An J, Pastor WA, Koralov SB, Rajewsky K, Rao A . TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol Rev 2015; 263: 6–21.

    Article  CAS  Google Scholar 

  15. Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012; 150: 1135–1146.

    Article  CAS  Google Scholar 

  16. Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2013; 32: 663–669.

    Article  CAS  Google Scholar 

  17. Hsu CH, Peng KL, Kang ML, Chen YR, Yang YC, Tsai CH et al. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep 2012; 2: 568–579.

    Article  CAS  Google Scholar 

  18. Taylor MA, Wappett M, Delpuech O, Brown H, Chresta CM . Enhanced MAPK signaling drives ETS1-mediated induction of miR-29b leading to downregulation of TET1 and changes in epigenetic modifications in a subset of lung SCC. Oncogene 2016; 35: 4345–4357.

    Article  CAS  Google Scholar 

  19. Forloni M, Gupta R, Nagarajan A, Sun LS, Dong Y, Pirazzoli V et al. Oncogenic EGFR represses the TET1 DNA demethylase to induce silencing of tumor suppressors in cancer cells. Cell Rep 2016; 16: 457–471.

    Article  CAS  Google Scholar 

  20. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511: 543–550.

    Article  Google Scholar 

  21. Ni K, Dansranjavin T, Rogenhofer N, Oeztuerk N, Deuker J, Bergmann M et al. TET enzymes are successively expressed during human spermatogenesis and their expression level is pivotal for male fertility. Hum Reprod 2016; 31: 1411–1424.

    Article  CAS  Google Scholar 

  22. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 2012; 22: 2109–2119.

    Article  CAS  Google Scholar 

  23. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK . Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 2014; 14: 535–546.

    Article  CAS  Google Scholar 

  24. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014; 346: 256–259.

    Article  CAS  Google Scholar 

  25. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014; 346: 251–256.

    Article  CAS  Google Scholar 

  26. Midha A, Dearden S, McCormack R . EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 2015; 5: 2892–2911.

    PubMed  PubMed Central  Google Scholar 

  27. Dearden S, Stevens J, Wu YL, Blowers D . Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 2013; 24: 2371–2376.

    Article  CAS  Google Scholar 

Download references


We acknowledge the technical services provided by Clinical Medicine Research Laboratory of National Yang-Ming University Hospital, especially the technical support of Ping-Liang Hung, Peng-Chih Chiu, Chia-Yuan Huang for their assistance.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Author information

Authors and Affiliations


Corresponding author

Correspondence to S-C Chang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lai, JI., Lai, YC., Chen, YC. et al. Clinical analysis of NSCLC patients reveals lack of association between EGFR mutation and TET1 downregulation. Cancer Gene Ther 24, 373–380 (2017).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links